Evidence map›Paper›PMID 29147831›Full record

ArticleJournal of bioenergetics and biomembranes2017

Plants of Brazilian restingas with tripanocide activity against Trypanosoma cruzi strains.

Robson Xavier Faria, André Luis Almeida Souza, Barbara Lima, Luis Armando Candido Tietbohl, Caio Pinho Fernandes, Raquel Rodrigues Amaral, Bettina Monika Ruppelt, Marcelo Guerra Santos, Leandro Rocha

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bioenergetics and biomembranes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Molluskicidal nanoemulsion ofFrontiers in pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Robson Xavier FariaLaboratório de Toxoplasmose e outras Protozooses- Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. robson.xavier@gmail.com.
André Luis Almeida SouzaLaboratório de Bioquímica de Peptídeos- Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Barbara LimaLaboratório de Tecnologia de Produtos Naturais - Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
Luis Armando Candido TietbohlLaboratório de Tecnologia de Produtos Naturais - Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
Caio Pinho FernandesLaboratório de Pesquisa em Fármacos - Departamento de Ciências Biológicas e da Saúde, Universidade Federal do Amapá, Macapá, Brazil.
Raquel Rodrigues AmaralLaboratório de Nanobiotecnologia Fitofarmacêutica - Curso de Ciências Farmacêuticas, Universidade Federal do Amapá, Macapá, Brazil.
Bettina Monika RuppeltLaboratório Universitário Rodolpho Albino - Pró-Reitoria de Extensão, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
Marcelo Guerra SantosDepartamento de Ciências, Faculdade de Formação de Professores, Universidade do Estado do Rio de Janeiro, São Gonçalo, RJ, Brazil.
Leandro RochaLaboratório de Tecnologia de Produtos Naturais - Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
Universidade Federal Fluminense · BRFundação Oswaldo Cruz · BRUniversidade Federal do Amapá · BRUniversidade do Estado do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease is caused by the Trypanosoma cruzi affecting millions of people, and widespread throughout Latin America. This disease exhibits a problematic chemotherapy. Benznidazole, which is the drug currently used as standard treatment, lamentably evokes several adverse reactions. Among other options, natural products have been tested to discover a novel therapeutic drug for this disease. A lot of plants from the Brazilian flora did not contain studies about their biological effects. Restinga de Jurubatiba from Brazil is a sandbank ecosystem poorly studied in relation to plant biological activity. Thus, three plant species from Restinga de Jurubatiba were tested against in vitro antiprotozoal activity. Among six extracts obtained from leaves and stem parts and 2 essential oils derived from leave parts, only 3 extracts inhibited epimastigote proliferation. Substances present in the extracts with activity were isolated (quercetin, myricetin, and ursolic acid), and evaluated in relation to antiprotozoal activity against epimastigote Y and Dm28 Trypanosoma cruzi strains. All isolated substances were effective to reduce protozoal proliferation. Essentially, quercetin and myricetin did not cause mammalian cell toxicity. In summary, myricetin and quercetin molecule can be used as a scaffold to develop new effective drugs against Chagas's disease.

Indexed as

EcosystemAnimalsAntiprotozoal AgentsBrazilCell LineChagas DiseaseFlavonoidsHumansPlant ExtractsQuercetinTrypanosoma cruziAntiprotozoal AgentsFlavonoidsmyricetinPlant ExtractsQuercetinBrazilianPlantsRestingasTrypanocideTrypanossoma cruzi

Identifiers

PMID29147831
OpenAlexW2768643474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.